The impact of the illness label 'gout' on illness and treatment perceptions in Māori (Indigenous New Zealanders).
Arthritis
Gout
Illness perceptions
Urate
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
05
2019
accepted:
13
02
2020
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
22
4
2020
Statut:
epublish
Résumé
Despite contemporary advances in understanding pathogenesis and effective management of gout, beliefs about the disease continue to be focused on gout as a self-inflicted illness. The illness label itself may contribute to inaccurate perceptions of the disease and its management. In Aotearoa/New Zealand, Māori (Indigenous New Zealanders) have high prevalence of severe gout. The aim of this study was to examine the impact of the illness label 'gout' on perceptions of the disease and its management for Māori. Māori supermarket shoppers ( 'Gout' was most likely to be viewed as caused by diet, whereas 'urate crystal arthritis' was most likely to be viewed as caused by aging. 'Urate crystal arthritis' was seen as having a wider range of factors responsible for the illness, including stress or worry, hereditary factors and chance. 'Gout' was less likely to be viewed as having a chronic timeline, and was perceived as being better understood. Dietary management strategies were seen as more helpful for management of the gout-labelled illness. This study has demonstrated that for Māori, Indigenous New Zealanders who are disproportionately affected by gout, the illness label influences perceptions about gout and beliefs about management.
Sections du résumé
BACKGROUND
BACKGROUND
Despite contemporary advances in understanding pathogenesis and effective management of gout, beliefs about the disease continue to be focused on gout as a self-inflicted illness. The illness label itself may contribute to inaccurate perceptions of the disease and its management. In Aotearoa/New Zealand, Māori (Indigenous New Zealanders) have high prevalence of severe gout. The aim of this study was to examine the impact of the illness label 'gout' on perceptions of the disease and its management for Māori.
METHODS
METHODS
Māori supermarket shoppers (
RESULTS
RESULTS
'Gout' was most likely to be viewed as caused by diet, whereas 'urate crystal arthritis' was most likely to be viewed as caused by aging. 'Urate crystal arthritis' was seen as having a wider range of factors responsible for the illness, including stress or worry, hereditary factors and chance. 'Gout' was less likely to be viewed as having a chronic timeline, and was perceived as being better understood. Dietary management strategies were seen as more helpful for management of the gout-labelled illness.
CONCLUSIONS
CONCLUSIONS
This study has demonstrated that for Māori, Indigenous New Zealanders who are disproportionately affected by gout, the illness label influences perceptions about gout and beliefs about management.
Identifiants
pubmed: 32313870
doi: 10.1186/s41927-020-00120-z
pii: 120
pmc: PMC7158036
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsNicola Dalbeth declares that she has received speaking fees from Pfizer, Horizon, Janssen, and AbbVie, consulting fees from Horizon, Hengrui, Arthrosi, Dyve BioSciences, and Kowa, and research funding from Amgen and AstraZeneca, and is currently principal investigator on a clinical trial of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). She also declares that within the past 5 years she has been principal investigator on a clinical trial of febuxostat in early gout and has received consulting or speaking fees from Takeda, Menarini, and Teijin. The other authors have no conflicts of interest to disclose.
Références
BMJ. 2012 Jan 12;344:d8190
pubmed: 22240117
Health Psychol. 2018 Jan;37(1):37-41
pubmed: 28836797
Psychol Health. 2015;30(11):1361-85
pubmed: 26181764
Arthritis Rheum. 2002 Aug;47(4):356-60
pubmed: 12209479
Arthritis Care Res (Hoboken). 2018 May;70(5):659-671
pubmed: 29649348
J Prim Health Care. 2013 Sep 01;5(3):214-22
pubmed: 23998172
Clin Rheumatol. 2013 Feb;32(2):247-51
pubmed: 23114632
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Br J Health Psychol. 2012 Feb;17(1):74-84
pubmed: 22107110
Psychosom Med. 2002 Jul-Aug;64(4):580-6
pubmed: 12140347
Bull Hist Med. 1994 Spring;68(1):1-28
pubmed: 8173299
N Z Med J. 2018 Nov 9;131(1485):8-12
pubmed: 30408813
Lancet. 2016 Oct 22;388(10055):2039-2052
pubmed: 27112094
Arthritis Care Res (Hoboken). 2016 Nov;68(11):1721-1725
pubmed: 27134185
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1605-12
pubmed: 22034122
Arthritis Care Res (Hoboken). 2019 Mar;71(3):419-426
pubmed: 29781577
J Clin Rheumatol. 2012 Apr;18(3):125-9
pubmed: 22426580
BMJ. 2018 Aug 12;362:k3322
pubmed: 30100549
Rheumatology (Oxford). 2018 Jul 1;57(7):1282-1292
pubmed: 29672772
Psychol Bull. 2017 Nov;143(11):1117-1154
pubmed: 28805401
Health Psychol Rev. 2019 Dec;13(4):406-426
pubmed: 30558520
Rheumatology (Oxford). 2012 May;51(5):901-9
pubmed: 22253023
J Prim Health Care. 2018 Oct;10(3):194-200
pubmed: 31039932
J Clin Rheumatol. 2011 Jan;17(1):1-6
pubmed: 21169857
Arthritis Res Ther. 2006;8 Suppl 1:S1
pubmed: 16820040
Ann Rheum Dis. 2010 Jul;69(7):1305-9
pubmed: 19592386
Ann Intern Med. 1966 Feb;64(2):229-58
pubmed: 5322938
Ann Rheum Dis. 2012 Sep;71(9):1490-5
pubmed: 22440822
Ann Rheum Dis. 2007 Aug;66(8):1056-8
pubmed: 17223663
Semin Arthritis Rheum. 2018 Apr;47(5):689-702
pubmed: 29198878
Nat Genet. 2013 Feb;45(2):145-54
pubmed: 23263486